Pipeline

Synergy IMT groundbreaking therapeutics with potential as standalone or combination therapy to treat a broad range of cancers

Our Pipeline

Synergy IMT is committed to progressing an initial candidate into clinical studies and forming collaborations around other candidates

SYN220

An antibody drug conjugate (ADC) that targets an antigen identified at Synergy IMT that is broadly expressed on different tumor types including colon, breast, gastric and pancreatic. A tumor antigen selected for direct tumor cytotoxicity, anti-metastatic and anti- protumor microenvironment activity.

SYN120

A bispecific T cell engaging antibody that targets a solid tumor antigen identified at Synergy IMT. A tumor antigen selected for direct tumor cytotoxicity, anti-metastatic and anti- protumor microenvironment activity

SYN320

Several multispecific recombinant proteins have been designed to target and induce tumor cytotoxicity.

Recombinant Protein Therapeutic
Colon Tumor Xenograft Study
Dosed IV @0.5mg/kg